We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
The chapter explores whether high-income countries are ready for the first disease-modifying Alzheimer’s disease (AD) treatment, approved in the USA in February 2021. It looks at the capacity to provide diagnostic services relative to the expected demand, institutional preparedness, and potential solutions to overcome capacity constraints. Wait times are projected to differ substantially. Initial average wait times range from 5 months in Germany to 28 months in Canada. In France, Canada, and Taiwan, we project it will take over a decade to clear the backlog of prevalent cases and to make a treatment accessible with little delay, because of scarcity of dementia specialists, and aggravated by the lack of financial and structural plannin. Potential solutions include broadening the dementia workforce by integration of primary care clinicians and other specialists, care models that leverage specialist time, and telecare-supported models. Better diagnostic technology to detect cognitive decline and the AD pathology in primary care settings and predictive models to triage patients show potential to improve access.
In children and adolescents, multiple sclerosis (MS) has an impact on the developing central nervous system, and can result in transient or fixed deficits of gross motor and/or fine motor skills, sensory perceptual processing, bowel/bladder function, vision, balance, and coordination. In this chapter, the evaluation and care of patients with symptoms of pediatric demyelinating disease are addressed as individual systems with discussion of anatomy and typical features, evaluation measures, and treatment options, including both non-pharmacologic and pharmacologic approaches. Fatigue is the most common symptom experienced by MS patients and is adversely correlated with quality of life. Minimizing fatigue in the pediatric MS population requires a multifaceted approach of eliminating unnecessary energy demands, improving sleep hygiene and optimizing symptomatic medication and disease-modifying treatment (DMT) regimens. The PedsSQ Multidimensional Fatigue Scale has been validated and used in other pediatric chronic diseases such as cancer, inflammatory bowel disease, and rheumatological diseases.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.